<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200509047376N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-11-24</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of APRV ventilation mode on respiratory failure</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of using Airway Pressure Release Ventilation (APRV) in comparison with Pressure Support Ventilation (PSV) method in lung mechanics in patients with Acute Respiratory Failure (ARF) admitted to intensive care unit</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-11-12</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>52</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/52202</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The two groups are divided based on random numbers generated by computer software.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Acute hypoxemic respiratory failure.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: APRV: Patients change from previous volume ventilation mode to APRV mode. P-high is adjusted to create VT = 6ml / kg and does not exceed 30cmH2O. From 60%, produce PaO2 above 60. The T-low is set to 1 to 1.5 times the expiratory time constant (TE). T-high is adjusted so that the release frequency is set to 10-14 / min and PaCO2 is maintained in the normal range. Intervention 2: Control group: PSV: Patients on pressure mode with PIP and PS with the aim of creating a tidal volume equal to 6 ml per kg of ideal weight. PEEP to the extent that with FIO2 less than 60%, PaO2 above 60 Slowly adjusted.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Individual data is recorded and archived in the datasheet. All data can be shared after unidentifiable study subjects.

When:
Access period starts 6 months after the results are published

To whom:
Only for researchers working in academic and scientific institutions

Conditions:
No other analysis is allowed.

Where to obtain:
En To receive the data, they can send a request to the following email address. elhamnaseh63@gmail.com

How to obtain:
En To receive the data, they can send a request to the following email address. elhamnaseh63@gmail.com. Information will be made available to eligible individuals within 24 hours.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Elham Naseh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tehran University of Medical Science, Poorsin street, Keshavarz ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 84901</telephone>
        <email>elhamnaseh63@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Atabak Najafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sina Hospital, Imam Khomeini Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6634 8500</telephone>
        <email>elhamnaseh63@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Intubated patients with acute respiratory failure type I (hypoxemic)
Endotracheal intubation and mechanical ventilation less than 48 hours
Respiratory failure based on P / F Ratio = 150-250</inclusion_criteria>
      <agemin>16 years</agemin>
      <agemax>85 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with acute respiratory failure and P / F Ratio less than 150
Neuromuscular and diaphragmatic disorders
Chest deformity
Suspected Intracranial Hypertension
COPD and  severe asthma
CHF
CKD , ESRD
Refractory shock
Diagnosed Barotrauma and Lung Contusion
Age under 16 and over 85 years
Pregnancy
Abdominal compartment syndrome</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J96.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute respiratory failure</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: APRV: Patients change from previous volume ventilation mode to APRV mode. P-high is adjusted to create VT = 6ml / kg and does not exceed 30cmH2O. From 60%, produce PaO2 above 60. The T-low is set to 1 to 1.5 times the expiratory time constant (TE). T-high is adjusted so that the release frequency is set to 10-14 / min and PaCO2 is maintained in the normal range.</i_keyword>
      <i_keyword>Control group: PSV: Patients on pressure mode with PIP and PS with the aim of creating a tidal volume equal to 6 ml per kg of ideal weight. PEEP to the extent that with FIO2 less than 60%, PaO2 above 60 Slowly adjusted.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Lung compliance. Lung resistance. Timepoint: Measurement of lung compliance and resistance on days 1, 2, 3 and 7 after long-term onset of APRV and PSV. Method of measurement: compliance and resistance measurment is based on ventilator information.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II Scoring System. Timepoint: At the time of admission. Method of measurement: According to the case report.</sec_outcome>
      <sec_outcome>Oxygenation based on the ratio of arterial oxygen pressure to the Fio2. Timepoint: Days 1, 2, 3 and 7 after the start of ventilation mode. Method of measurement: Based on sample information of ABG blood gas analysis.</sec_outcome>
      <sec_outcome>Arterial blood carbon dioxide pressure PaCO2. Timepoint: Days 1, 2, 3 and 7 after the start of ventilation mode. Method of measurement: Based on sample information of ABG blood gas analysis.</sec_outcome>
      <sec_outcome>Fentanyl intake. Timepoint: روزهای 1و2و3و7 بعد از شروع مد تهویه ای. Method of measurement: Based on patient record (micrograms).</sec_outcome>
      <sec_outcome>Number of ventilator free days at day 28. Timepoint: Twenty-eighth day after intervention. Method of measurement: Based on patient record.</sec_outcome>
      <sec_outcome>Intensive care unit length of stay. Timepoint: At the time of discharge from the intensive care unit. Method of measurement: Based on patient record.</sec_outcome>
      <sec_outcome>Richmond Agitation and Sedation Scale (RASS score). Timepoint: Days 1, 2, 3 and 7 after the start of ventilation mode. Method of measurement: Based on patient record.</sec_outcome>
      <sec_outcome>The amount of shunt:    (1-SaO2)/(1-SvO2). Timepoint: Days 1, 2, 3 and 7 after the start of ventilation mode. Method of measurement: Based on ABG information.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-02-23</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Sina Hospital, Imam Khomeini Ave.,Imam Khomeini Square Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
